Drugs / L19TNFα
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02076620 | Jan 2013 → Jan 2018 | — | Philogen S.p.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L19TNFα | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02076620 ↗ |
| Modality | Protein / enzyme biologic | “Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein” NCT02076620 ↗ |
| Route | Intravenous | “L19TNFα will be administered as a 2 hours i.v. infusion” NCT02076620 ↗ |